Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Schett
Steven L Teitelbaum

Showing results (91-100 of 1,160) with videos related to

Pageof 116
Sort By:
Trends in Molecular Medicine|May 13, 2008
Molecular mechanisms of inflammatory bone damage: emerging targets for therapySonja Herman, Gerhard Krönke, Georg Schett
Cell|August 19, 2007
Bone weighs in on obesityClay F Semenkovich, Steven L Teitelbaum
Immunological Reviews|November 30, 2005
alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biologyF Patrick Ross, Steven L Teitelbaum
Annual Review of Pathology|November 28, 2007
The osteoclast: friend or foe?Deborah V Novack, Steven L Teitelbaum
Lancet (London, England)|September 25, 2023
CAR T-cell therapy in autoimmune diseasesGeorg Schett, Andreas Mackensen, Dimitrios Mougiakakos
Frontiers in Immunology|July 24, 2019
How Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid ArthritisUlrike Steffen, Georg Schett, Aline Bozec
Nature Reviews. Genetics|August 5, 2003
Genetic regulation of osteoclast development and functionSteven L Teitelbaum, F Patrick Ross
Inflammation & Allergy Drug Targets|January 28, 2012
Inflammation-associated changes in bone homeostasisCarina Scholtysek, Gerhard Krönke, Georg Schett
Arthritis & Rheumatology (Hoboken, N.J.)|May 29, 2019
Development of Joint Erosions in the Preclinical Phase of Rheumatoid Arthritis Depicted by Cinematic RenderingDavid Simon, Georg Schett, Arnd Kleyer
The New England Journal of Medicine|November 3, 2021
More on CD19-CAR T Cells in Systemic Lupus Erythematosus. ReplyDimitrios Mougiakakos, Gerhard Krönke, Georg Schett
Pageof 116

Showing results (91-100 of 1,160) with videos related to

Sort By:
Pageof 116
Trends in Molecular Medicine|May 13, 2008
Molecular mechanisms of inflammatory bone damage: emerging targets for therapySonja Herman, Gerhard Krönke, Georg Schett
Cell|August 19, 2007
Bone weighs in on obesityClay F Semenkovich, Steven L Teitelbaum
Immunological Reviews|November 30, 2005
alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biologyF Patrick Ross, Steven L Teitelbaum
Annual Review of Pathology|November 28, 2007
The osteoclast: friend or foe?Deborah V Novack, Steven L Teitelbaum
Lancet (London, England)|September 25, 2023
CAR T-cell therapy in autoimmune diseasesGeorg Schett, Andreas Mackensen, Dimitrios Mougiakakos
Frontiers in Immunology|July 24, 2019
How Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid ArthritisUlrike Steffen, Georg Schett, Aline Bozec
Nature Reviews. Genetics|August 5, 2003
Genetic regulation of osteoclast development and functionSteven L Teitelbaum, F Patrick Ross
Inflammation & Allergy Drug Targets|January 28, 2012
Inflammation-associated changes in bone homeostasisCarina Scholtysek, Gerhard Krönke, Georg Schett
Arthritis & Rheumatology (Hoboken, N.J.)|May 29, 2019
Development of Joint Erosions in the Preclinical Phase of Rheumatoid Arthritis Depicted by Cinematic RenderingDavid Simon, Georg Schett, Arnd Kleyer
The New England Journal of Medicine|November 3, 2021
More on CD19-CAR T Cells in Systemic Lupus Erythematosus. ReplyDimitrios Mougiakakos, Gerhard Krönke, Georg Schett
Pageof 116